ABVC BIOPHARMA, INC. UNDERWRITING AGREEMENT 1,100,000 Units Consisting of 1,100,000 Shares of Common Stock 1,100,000 Series A Warrants to Purchase 1,100,000 Shares of Common Stock And 1,100,000 Series B Warrants to Purchase 1,100,000 Shares of Common...Underwriting Agreement • August 5th, 2021 • Abvc Biopharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 5th, 2021 Company Industry JurisdictionABVC BIOPHARMA, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as representative (the “Representative”), an aggregate of 1,100,000 Units (the “Firm Units”), each Firm Unit consisting of (a) one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (b) one Series A warrant (the “Series A Warrants”) to purchase one share of Common Stock and (c) one Series B warrant to purchase one share of common stock (the “Series B Warrants,” and together with the Series A Warrants, the “Warrants” and each a “Warrant”). The 1,100,000 shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Uni
ABVC BIOPHARMA, INC. UNDERWRITING AGREEMENT 1,000,000 Units Consisting of 1,000,000 Shares of Common Stock 1,000,000 Series A Warrants to Purchase 1,000,000 Shares of Common Stock And 1,000,000 Series B Warrants to Purchase 1,000,000 Shares of Common...Underwriting Agreement • July 21st, 2021 • Abvc Biopharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 21st, 2021 Company Industry JurisdictionABVC BIOPHARMA, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as representative (the “Representative”), an aggregate of 1,000,000 Units (the “Firm Units”), each Firm Unit consisting of (a) one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (b) one Series A warrant (the “Series A Warrants”) to purchase one share of Common Stock and (c) one Series B warrant to purchase one share of common stock (the “Series B Warrants,” and together with the Series A Warrants, the “Warrants” and each a “Warrant”). The 1,000,000 shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Uni
Phio Pharmaceuticals Corp. [________] Shares of Common Stock Pre-Funded Warrants to Purchase [________] Shares of Common Stock and Warrants to Purchase [________] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 31st, 2020 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 31st, 2020 Company Industry JurisdictionPhio Pharmaceuticals Corp., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) [________] shares of common stock (the “Firm Shares”), par value $0.0001 per share, of the Company (the “Common Stock”) and (b) [________] pre-funded warrants to purchase [________] shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”); and (ii) [________] warrants to purchase [________] shares of Common Stock (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of the Underwriter, up to an additional [________] shares of Common Stock (the “Option Shares”) and/or warra
OpGen, Inc. 2,590,170 Shares of Common Stock Pre-Funded Warrants to Purchase 2,109,830 Shares of Common Stock and Warrants to Purchase 4,700,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 28th, 2019 • Opgen Inc • Services-medical laboratories • New York
Contract Type FiledOctober 28th, 2019 Company Industry JurisdictionOpGen, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 2,590,170 shares of common stock (the “Firm Shares”), par value $0.01 per share, of the Company (the “Common Stock”) and (b) 2,109,830 pre-funded warrants to purchase 2,109,830 shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) warrants to purchase 4,700,000 shares of Common Stock (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of the Underwriter, up to an additional 705,000 shares of Common Stock (the “Option Shares”) and/or warrants to purchase up to an aggregate o
OpGen, Inc. [●] Shares of Common Stock Pre-Funded Warrants to Purchase [●] Shares of Common Stock and Warrants to Purchase [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 15th, 2019 • Opgen Inc • Services-medical laboratories • New York
Contract Type FiledOctober 15th, 2019 Company Industry JurisdictionOpGen, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) [●] shares of common stock (the “Firm Shares”), par value $0.01 per share, of the Company (the “Common Stock”) and (b) [●] pre-funded warrants to purchase [●] shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) warrants to purchase [●] shares of Common Stock (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of the Underwriter, up to an additional [●] shares of Common Stock (the “Option Shares”) and/or warrants to purchase up to an aggregate of [●] shares of Common Stock
InspireMD, Inc. [●] Shares of Common Stock Pre-Funded Warrants to Purchase [●] Shares of Common Stock and Warrants to Purchase [●] Shares of Common StockUnderwriting Agreement • September 13th, 2019 • InspireMD, Inc. • Surgical & medical instruments & apparatus • New York
Contract Type FiledSeptember 13th, 2019 Company Industry JurisdictionInspireMD, Inc., Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) [●] shares of common stock (the “Firm Shares”), par value $0.0001 per share, of the Company (the “Common Stock”) and (b) [●] pre-funded warrants to purchase [●] shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) [●] Series E warrants to purchase [●] shares of Common Stock (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of the Underwriter, up to an additional [●] shares of Common Stock (the “Option Shares”) and/or Series E warrants to purchase up to an aggre
InspireMD, Inc. [●] Shares of Common Stock Pre-Funded Warrants to Purchase [●] Shares of Common Stock and Warrants to Purchase [●] Shares of Common StockUnderwriting Agreement • June 26th, 2018 • InspireMD, Inc. • Surgical & medical instruments & apparatus • New York
Contract Type FiledJune 26th, 2018 Company Industry JurisdictionInspireMD, Inc., Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) [•] shares of common stock (the “Firm Shares”), par value $0.0001 per share, of the Company (the “Common Stock”) and (b) [ •] pre-funded warrants to purchase [●] shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) [●] Series D warrants to purchase [●] shares of Common Stock (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of the Underwriter, up to an additional [●] shares of Common Stock (the “Option Shares”) and/or Series D warrants to purchase up to an aggr